Announcements Trials
Browse Landscape

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 17Observational 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Follicular 1

Interventions

Rituximab 6Polymerase Chain Reaction 6Amplified Fragment Length Polymorphism Analysis 6Gene Expression Profiling 5obinutuzumab 4Surveys and Questionnaires 4Psychiatric Rehabilitation 4Microarray Analysis 4Immunohistochemistry 4Flow Cytometry 4Therapeutics 3Immunoenzyme Techniques 3Drug Therapy 3tisagenlecleucel 2duvelisib 2Prednisone 2Lenalidomide 2Influenza Vaccines 2Immunologic Techniques 2Echocardiography 2Blood Specimen Collection 2zanubrutinib 1tazemetostat 1relmacabtagene autoleucel 1pomalidomide 1ibritumomab tiuxetan 1deucravacitinib 1Watchful Waiting 1Waiting Lists 1Vincristine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Lymphoma, Follicular × tazemetostat × Clear all
NCT05228158 2026-01-02

A Study of Tazemetostat on Safety in Participants With Relapsed or Refractory Follicular Lymphoma With Enhancer of Zeste Homolog 2 (EZH2) Gene Mutation in Japan

Eisai Inc.

Active not recruiting
145 enrolled
Lymphoid

Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡